Drugs / LV-NYESO TCR /sr39TK PBSC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03506802 | Jul 2018 → Jun 2019 | plasma cell myeloma | Jonsson Comprehensive Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LV-NYESO TCR /sr39TK PBSC | “LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV” NCT03506802 ↗ |
| Action | Deplete | “redirected to attack and kill the cancer cells” NCT03506802 ↗ |
| Modality | Cell therapy | “TCR transduced autologous PBMC and CD34+ PBSC” NCT03506802 ↗ |
| Route | Intravenous | “LV-NYESO TCR /sr39TK PBSC and RV-NYESO TCR PBMC given IV” NCT03506802 ↗ |